	LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)		ATTY DOCKET NO. 9516-083-999 (CAM: 501872-999082)	APPLICATION NO. 10/699,110
	APPLICANT Zeldis			
	FILING DATE 10-30-03	GROUP 1614		

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ZF	A01	10/105,833	03-25-02	Muller			
	A02	10/243,927	09-13-02	Muller			
	A03	10/316,673	12-11-02	Muller et al.			
	A04	60/436,975	12-30-02	Muller et al.			
	A05	60/438,448	01-07-03	Müller et al.			
	A06	60/438,450	01-07-03	Muller et al.			
	A07	60/438,450	01-07-03	Muller et al.			
	A08	60/438,448	01-07-03	Muller et al.			
	A09	60/452,460	03-05-03	Muller et al.			
	A10	60/452,460	03-05-03	Muller et al.			
	A11	60/454,149	03-12-03	Muller et al.			
	A12	60/454,155	03-12-03	Muller et al.			
	A13	60/454,149	03-12-03	Man et al.			
	A14	10/798,372	03-12-03	Man et al.			
	A15	10/392,195	03-19-03	Schafer et al.			
	A16	10/392,195	03-19-03	Muller et al.			
	A17	10/462,319	06-16-03	Muller et al.			
	A18	10/622,618	07-17-03	Muller et al.			
	A19	10/685,942	10-14-03	Man et al.			
	A20	10/715,184	11-17-03	Muller et al.			
	A21	10/748,085	12-29-03	Man et al.			
	A22	10/786,822	02-25-04	Man et al.			
	A23	10/794,931	03-05-04	Muller et al.			
ZF	A24	3,536,809	10-27-70	Applezweig			
	A25	3,598,123	08-10-71	Zaffaroni			
	A26	3,845,770	11-05-74	Theeuwes et al.			
	A27	3,916,899	11-04-75	Theeuwes et al.			
	A28	4,008,719	02-22-77	Theeuwes et al.			
ZF	A29	5,059,595	10-22-91	La Grazie			

2.F	A30	5,073,543	12-17-91	Marshall et al.			
	A31	5,120,548	06-09-92	McClelland et al.			
	A32	5,354,556	10-11-94	Sparks et al.			
	A33	5,463,063	10-31-95	Muller			
	A34	5,591,767	01-07-97	Mohr et al.			
	A35	5,605,914	02-25-97	Muller			
	A36	5,632,984	05-27-97	Wong et al.			
	A37	5,639,476	06-17-97	Oshlack et al.			
	A38	5,658,940	08-19-97	Muller et al.			
	A39	5,674,533	10-07-97	Santus et al.			
	A40	5,698,579	12-16-97	Muller.			
	A41	5,703,098	12-30-97	Muller			
	A42	5,728,844	03-17-98	Muller			
	A43	5,728,845	03-17-98	Muller			
	A44	5,733,566	03-31-98	Lewis			
	A45	5,736,570	04-07-98	Muller			
	A46	5,770,589	06-23-98	Billson			
	A47	5,801,195	09-01-98	Muller et al.			
	A48	5,877,200	03-02-99	Muller			
	A49	5,929,117	07-27-99	Muller et al.			
	A50	5,968,945	10-19-99	Muller et al.			
	A51	6,001,368	12-14-99	Jenks			
	A52	6,011,050	01-04-00	Muller et al.			
	A53	6,015,803	01-18-00	Wirostko			
	A54	6,020,358	01-04-00	Muller et al.			
	A55	6,046,221	04-04-00	Muller et al.			
	A56	6,130,226	10-10-00	Muller et al.			
	A57	6,180,644	01-30-01	Muller et al.			
	A58	6,200,987	03-13-01	Muller			
	A59	6,214,857	04-10-01	Muller et al.			
	A60	6,218,369	04-17-01	Bombardelli et al.			
	A61	6,225,348	05-01-01	Paulson			
	A62	6,262,101	07-17-01	Muller et al.			
	A63	6,284,780	09-04-01	Muller et al.			
	A64	6,326,388	12-04-01	Man et al.			
	A65	6,429,221	08-06-02	Muller et al.			
	A66	6,479,554	11-12-02	Muller et al.			
2.F	A67	6,518,281	02-11-03	Muller et al.			

	A68	6,656,964	12-02-03	Muller et al.			
	A69	6,667,316	12-23-04	Man et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
ZF	A70	WO 03/080048	10-02-03	PCT				
	A71	WO 03/080049	10-02-03	PCT				
	A72	WO 01/34606	05-17-01	PCT				
	A73	WO 01/45702	06-28-01	PCT				
	A74	WO 95/01348	01-12-95	PCT				
	A75	WO 97/08143	03-06-97	PCT				
	A76	WO 97/23457	07-03-97	PCT				
ZF	A77	WO 99/06041	02-11-99	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

ZF	A78	1 Burger's Medicinal Chemistry and Drug Discovery, 172-178, 949-982 (Manfred E. Wolff ed., 5th ed. 1995)
ZF	A79	Corral, et al., Ann. Rheum. Dis. 58:(Suppl I) 1107-1113 (1999)

EXAMINER

Zohr Fag

DATE CONSIDERED

4/28/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY DOCKET NO. 9516-083-999 (CAM: 501872-999082)	APPLICATION NO. 10/699,110
	APPLICANT Zeldis	
	FILING DATE 10-30-03	GROUP 1614
U.S. PATENT DOCUMENTS		




*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
ZF	A80	5,770,589	06/23/98	Billson <i>et al.</i>	514	174	

FOREIGN PATENT DOCUMENTS								
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
ZF	B01	WO 95/03807	09/02/95	PCT				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		

EXAMINER <i>Zahid Fay</i>	DATE CONSIDERED 4/28/07
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	


LIST OF REFERENCES CITED BY APPLICANT
 (Use several sheets if necessary)

ATTY DOCKET NO.

9516-083-999

APPLICATION NO.

10/699,110

APPLICANT

Zeldis

FILING DATE

October 30, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A82	5,770,589	6/23/98	Billson et al.			
Z.F.	A83	5,605,914	2/25/97	Muller			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

Z.F.	A84	Bressler, 1999, "Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP Report 1," Archives of Ophthalmol. 117(10):1329-1345
Z.F.	A85	Hunt, 2002, Rostaporfin (Miravant Medical Technologies) IDrugs 5(2):180-186
Z.F.	A86	Ohno-Matsui et al., 2001, "Novel mechanism for age-related macular degeneration: an equilibrium shift between the angiogenesis factors FEGF and PEDF," J. Cell. Physiol. 189(3):323-333

EXAMINER

Zahid Fay

DATE CONSIDERED

4/28/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.